Patent search cpc:"C07D263/48" Page 1

1.

发明授权
Aryl hydrocarbon receptor (AHR) agonists and uses thereof 有权

公开(公告)号：US12030876B2

公开(公告)日：2024-07-09

申请号：US18166689

申请日：2023-02-09

Applicant: Ikena Oncology, Inc.

Inventor： Alfredo C. Castro , Karen J. McGovern , Michael Burke

IPC: A61K31/426 , A61P1/00 , A61P29/00 , C07D235/00 , C07D249/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/42 , C07D277/48 , C07D285/135 , C07D333/36 , C07D417/04 , C07D417/12

CPC classification number: C07D417/04 , A61K31/426 , A61P1/00 , A61P29/00 , C07D235/00 , C07D249/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/42 , C07D277/48 , C07D285/135 , C07D333/36 , C07D417/12

Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.

2.

发明授权
Pharmaceutical compounds 有权

公开(公告)号：US11673870B2

公开(公告)日：2023-06-13

申请号：US17108266

申请日：2020-12-01

Applicant: Sareum Limited

Inventor： John Charles Reader

IPC: C07D263/48 , A61P29/00 , A61P17/06 , A61P37/06 , C07D413/12

CPC classification number: C07D263/48 , A61P17/06 , A61P29/00 , A61P37/06 , C07D413/12

Abstract: The invention provides a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of a compound having the formula (0):

or a salt or stereoisomer thereof. The invention also provides a novel subset of compounds within formula (0) as well as pharmaceutical compositions containing them and their use in medicine.

3.

发明申请
NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION 审中-公开

公开(公告)号：US20180230092A1

公开(公告)日：2018-08-16

申请号：US15933098

申请日：2018-03-22

Applicant: DREXEL UNIVERSITY , BARUCH S. BLUMBERG INSTITUTE , ARBUTUS BIOPHARMA, INC.

Inventor： XIAODONG XU , JU-TAO GUO , TONG XIAO , YANMING DU , TIMOTHY BLOCK , SIMON DAVID PETER BAUGH , HONG YE

IPC: C07C311/16 , C07D319/16 , C07D309/04 , C07D305/08 , C07D295/32 , C07D295/30 , C07D295/26 , C07D277/52 , C07D277/46 , C07D263/58 , C07D263/50 , C07D263/48 , C07D261/14 , C07D239/26 , C07D231/42 , C07D231/40 , C07D217/24 , C07D215/42 , C07D215/38 , C07D213/76 , C07D213/75 , C07D213/40 , C07D211/96 , C07D205/04 , C07D203/26 , C07C317/14 , C07C311/48 , C07C311/20 , C07C311/19 , C07C311/18 , C07C311/17 , C07C309/89 , C07C233/66 , C07D319/18

CPC classification number: C07C311/16 , C07B2200/07 , C07C233/66 , C07C309/89 , C07C311/17 , C07C311/18 , C07C311/19 , C07C311/20 , C07C311/48 , C07C317/14 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D203/26 , C07D205/04 , C07D211/96 , C07D213/40 , C07D213/75 , C07D213/76 , C07D215/38 , C07D215/42 , C07D217/24 , C07D231/40 , C07D231/42 , C07D239/26 , C07D261/14 , C07D263/48 , C07D263/50 , C07D263/58 , C07D277/46 , C07D277/52 , C07D295/26 , C07D295/30 , C07D295/32 , C07D305/08 , C07D309/04 , C07D319/16 , C07D319/18

Abstract: The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.

4.

发明申请
Organic Electroluminescent Element, Compound for Use in the Element, and Light Emitting Device, Display Device, and Illumination Device Using the Element 审中-公开

公开(公告)号：US20180069179A1

公开(公告)日：2018-03-08

申请号：US15806660

申请日：2017-11-08

Applicant: UDC IRELAND LIMITED

Inventor： Koji Takaku , Yasunori Yonekuta , Wataru Sotoyama , Katsuyuki Youfu , Yuki Hirai , Tetsu Kitamura , Toru Watanabe , Tianhua Ouyang

IPC: H01L51/00 , C07D401/10 , C07C211/54 , C07C211/58 , C07D213/74 , C07D239/42 , C07D241/20 , C07D495/04 , C07D493/04 , C07D333/36 , C07D307/91 , C07D307/66 , C07D263/48

CPC classification number: H01L51/0058 , C07C211/54 , C07C211/58 , C07C2603/50 , C07D213/74 , C07D239/42 , C07D241/20 , C07D263/48 , C07D307/66 , C07D307/91 , C07D333/36 , C07D401/10 , C07D493/04 , C07D495/04 , H01L51/0054 , H01L51/006 , H01L51/0061 , H01L51/0065 , H01L51/0067 , H01L51/0068 , H01L2251/308

Abstract: The disclosure relates to organic electroluminescent elements, compounds for use in the elements, and devices using the elements, which include a compound represented by the following General Formula (1): where R1 to R3 and R6 to R8 each independently represents a hydrogen atom, which may be a deuterium atom, or a substituent with a Hammett substituent constant σp value of −0.15 or more, R5, R9 and R10 each independently represents a hydrogen atom or a substituent, L1 represents a divalent linking group, DG1 represents a donor group, and n1 represents 1 or 2, and where R1 to R3, R5 to R10, L1, and DG1 are not bound to each other to form a ring.

5.

发明授权
Compounds and methods for kinase modulation, and indications therefor 有权

公开(公告)号：US09844539B2

公开(公告)日：2017-12-19

申请号：US15260042

申请日：2016-09-08

Applicant: Plexxikon Inc.

Inventor： Guoxian Wu , Jiazhong Zhang , Yong-Liang Zhu , Chao Zhang , Prabha N. Ibrahim , Songyuan Shi , Wayne Spevak , Dean R. Artis , James Tsai

IPC: C07D239/02 , C07D213/72 , C07D285/12 , C07D261/04 , A01N43/54 , A61K31/519 , A61K31/44 , A61K31/41 , C07D213/75 , C07D213/82 , C07D215/12 , C07D215/20 , C07D215/38 , C07D239/48 , C07D263/48 , C07D417/12 , C07D471/04 , A61K31/42 , A61K31/437 , A61K31/444 , A61K31/47 , A61K31/5377 , A61K31/549 , A61K45/06 , C07D215/14 , C07D261/14 , C07D285/16 , A61K31/4439 , A61K31/505 , C07D213/76 , C07D239/49 , A61K31/506 , C07D417/04 , C07D213/74 , C07D231/40 , C07D285/135 , C07D401/12 , C07D405/12 , C07D409/12 , A61K31/415 , A61K31/433 , A61K31/4436 , A61K31/4545

CPC classification number: A61K31/44 , A61K31/415 , A61K31/42 , A61K31/433 , A61K31/437 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K31/549 , A61K45/06 , C07D213/74 , C07D213/75 , C07D213/76 , C07D213/82 , C07D215/12 , C07D215/14 , C07D215/20 , C07D215/38 , C07D231/40 , C07D239/48 , C07D239/49 , C07D261/14 , C07D263/48 , C07D285/135 , C07D285/16 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , A61K31/4427 , A61K2300/00

Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

6.

发明授权
Phenyl-guanidine derivatives 有权

公开(公告)号：US09745257B2

公开(公告)日：2017-08-29

申请号：US14348577

申请日：2012-10-10

Applicant: Universidad Nacional de Quilmes , Chemo Research, S.L.

Inventor： Pablo Lorenzano Menna , Daniel Fernando Alonso , Daniel Eduardo Gómez , Julieta Comin

IPC: A61K31/505 , A61K31/155 , C07D239/42 , C07C277/08 , C07C279/18 , C07D213/75 , C07D333/36 , C07D233/88 , C07D235/30 , C07D263/48 , C07D207/14 , C07D277/48 , C07D307/66

CPC classification number: C07C279/18 , A61K31/155 , A61K31/505 , C07C277/08 , C07D207/14 , C07D213/75 , C07D233/88 , C07D235/30 , C07D239/42 , C07D263/48 , C07D277/48 , C07D307/66 , C07D333/36

Abstract: Provided herein are phenyl-guanidine derivatives for the inhibition of Rac1 which blocks its interaction with guanosine exchange factors (GEFs) belonging to the DBL family as agents for the treatment of aggressive and/or resistant tumors, as well as pharmaceutical compositions comprising them, their use in therapy and processes for their preparation.

7.

发明申请
THROMBOXANE RECEPTOR ANTAGONISTS 有权

公开(公告)号：US20170183300A1

公开(公告)日：2017-06-29

申请号：US15460910

申请日：2017-03-16

Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Inventor： B. Therese Kinsella , Patrick Guiry , Helen Reid , Barry O'Connor

IPC: C07C313/06

CPC classification number: C07D213/71 , A61K31/18 , A61K31/215 , A61K31/64 , C07C311/58 , C07C311/59 , C07C2601/14 , C07D205/04 , C07D213/34 , C07D213/53 , C07D213/85 , C07D213/89 , C07D231/12 , C07D261/08 , C07D263/48 , C07D277/34 , C07D295/192 , C07D305/08 , C07D307/42 , C07D307/52 , A61K2300/00

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

8.

发明申请
THROMBOXANE RECEPTOR ANTAGONISTS 有权
Title translation: 血栓素受体拮抗剂

公开(公告)号：US20170057913A1

公开(公告)日：2017-03-02

申请号：US15349379

申请日：2016-11-11

Applicant: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Inventor： B. Therese Kinsella , Patrick Guiry , Helen Reid , Barry O'Connor

IPC: C07C311/58

CPC classification number: C07D213/71 , A61K31/18 , A61K31/215 , A61K31/64 , C07C311/58 , C07C311/59 , C07C2601/14 , C07D205/04 , C07D213/34 , C07D213/53 , C07D213/85 , C07D213/89 , C07D231/12 , C07D261/08 , C07D263/48 , C07D277/34 , C07D295/192 , C07D305/08 , C07D307/42 , C07D307/52 , A61K2300/00

Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TPα) or TPbeta (TPβ) receptor subtype.

Abstract translation: 本发明一般涉及用作治疗血栓形成和其它心血管，肾或肺部疾病的TP拮抗剂的化合物。在一些实施方案中，本发明提供了包含取代的硝基苯氧基苯基，磺酰脲和烷基的化合物。在一些实施方案中，本发明提供了通过施用优先与血栓烷受体结合的抗血栓形成化合物治疗血栓形成的方法，具有TPalpha（TPα）或TPβ（TPβ）受体亚型的优先结合。